公开(公告)号：US20230167129A1

公开(公告)日：2023-06-01

申请号：US18045149

申请日：2022-10-08

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

公开(公告)号：US12065447B2

公开(公告)日：2024-08-20

申请号：US18045149

申请日：2022-10-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

公开(公告)号：US11498927B2

公开(公告)日：2022-11-15

申请号：US17289642

申请日：2019-10-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.